Kumarabharana rasa (KR) at a dose of 500 mg once daily for 30 days (Group A)	Godhuma Vati (placebo) at a dose of 500 mg once daily for 30 days (Group B)	fever	11806	11958	The comparisons on the effect of KR (study group) and Godhuma Vati (placebo group) on laboratory investigations and fever were nonsignificant (p > 0.05)
Kumarabharana rasa (KR) at a dose of 500 mg once daily for 30 days (Group A)	Godhuma Vati (placebo) at a dose of 500 mg once daily for 30 days (Group B)	mixed diet	9890	9947	A mixed diet was consumed by 80% (32) of the participants
Kumarabharana rasa (KR) at a dose of 500 mg once daily for 30 days (Group A)	Godhuma Vati (placebo) at a dose of 500 mg once daily for 30 days (Group B)	laboratory investigations	11806	11958	The comparisons on the effect of KR (study group) and Godhuma Vati (placebo group) on laboratory investigations and fever were nonsignificant (p > 0.05)
Kumarabharana rasa (KR) at a dose of 500 mg once daily for 30 days (Group A)	Godhuma Vati (placebo) at a dose of 500 mg once daily for 30 days (Group B)	laboratory investigations	11806	11982	The comparisons on the effect of KR (study group) and Godhuma Vati (placebo group) on laboratory investigations and fever were nonsignificant (p > 0.05) as detailed in Table 4.
Kumarabharana rasa (KR) at a dose of 500 mg once daily for 30 days (Group A)	Godhuma Vati (placebo) at a dose of 500 mg once daily for 30 days (Group B)	reduction of all signs and symptoms of chronic tonsillitis	1128	1272	Statistically significant effects (p < 0.05) in the reduction of all signs and symptoms of chronic tonsillitis after KR treatment were observed.
Kumarabharana rasa (KR) at a dose of 500 mg once daily for 30 days (Group A)	Godhuma Vati (placebo) at a dose of 500 mg once daily for 30 days (Group B)	fever	11806	11982	The comparisons on the effect of KR (study group) and Godhuma Vati (placebo group) on laboratory investigations and fever were nonsignificant (p > 0.05) as detailed in Table 4.
